CURE’s bladder cancer page is a go-to resource for oncology news and updates in the world of bladder cancer. Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in bladder cancer.
March 23rd 2018
Chemotherapy can aid in making a tumor “hot” – meaning that it attracts tumor-infiltrating lymphocytes (TILs), which are linked to killing tumor cells – priming it to respond better to immunotherapy treatment.
March 22nd 2018
After a recent FDA approval for an additional dosing schedule option for Opdivo, patients must be educated on the potential side effects that may occur between prolonged visits.
March 6th 2018
The Food and Drug Administration (FDA) has approved a supplemental biologics license application adding a four-week dosing schedule for Opdivo (nivolumab) across several of the PD-1 inhibitor’s indications.
February 14th 2018
Researchers from Israel, the United Kingdom (UK) and Canada sought to determine the cost-effectiveness of Keytruda for the second-line treatment of patients with advanced bladder cancer. Drug costs were compared between the US, UK, Canada and Australia.
February 10th 2018
Patients with diabetes are at a greater risk for bladder cancer, and worse, for disease recurrence and progression. So, recent research investigated if a certain diet would help.
February 5th 2018
Now that a number of immunotherapy agents have been approved in the bladder cancer space, identifying and managing the toxicities that may come along with them is critical.
January 25th 2018
Daniel J. George, M.D., discusses the role of immunotherapy, its continued integration into standards of care and what else the future holds for the treatment of bladder cancer.
January 5th 2018
“As the population of cancer survivors continues to grow, so does the importance of addressing the long-term sequelae of cancer treatment,” the authors wrote. “This hearing loss can result in multifaceted decrease in quality of life, and in pediatric patients it can impact social and academic development.”
December 26th 2017
When combined with other regimens in the treatment of patients with bladder cancer, immunotherapy has been shown to be beneficial, according to Arjun Balar, M.D.
December 13th 2017
To take the next step in this research, investigators are now combining immunotherapies together, or with chemotherapy, to create added benefits and more durable, long-lasting responses.
December 13th 2017
There were monumental advances in the treatment of bladder cancer during the year 2017, with five approvals for checkpoint inhibitors in both the first and second line setting
December 12th 2017
When given neoadjuvant chemotherapy before getting a radical cystectomy, patients with the basal subtype of muscle-invasive bladder cancer (MIBC) saw significantly improved overall survival (OS) compared to those who had a cystectomy alone, according to a recent study.
November 21st 2017
In the midst of all of the things that tie us together, it’s been what many would consider the most challenging shared experience a mother and son can have – facing and surviving cancer – that has been a defining feature of our relationship and ultimately one of the most overwhelming blessings of life.
October 7th 2017
Quality of care for patients being treated for urothelial carcinoma could be improved by having a multidisciplinary team treat the patient, says Robert Jones, M.D.
October 5th 2017
“It is not so much that the biology is changing; it’s that our knowledge of the biology is improving,” said Brant Inman, M.D.
October 2nd 2017
After years with few advancements, five new agents were approved to treat bladder cancer within the last year. CURE spoke with Terence Friedlander, M.D. about the shifting treatment paradigm for patients with the disease.